In October of 2015, Ferring Pharmaceuticals quietly initiated a voluntary, class 2 recall of Bravelle® (75 IU dose, injection-method, NDC 55566850506), for reasons of sub-potency. In other words, it did not contain the right amount of active ingredient.

This product defect was truly tragic for some women who may have permanently lost their chance to have children by taking sub-potent fertility medication. Andrews & Thornton successfully worked on behalf of affected women to recover millions in settlements for the cost of their fertility treatments and other injuries.